A 24-month, phase IV, open-label, single arm, multicenter, prospective, observational study assessing the efficacy and safety of subsequent treatment after initiation of intravitreal injection of ranibizumab 0.5 mg in diabetic macular edema patients with impaired visual acuity through individualized treatment in routine clinical practice in Japan

Trial Profile

A 24-month, phase IV, open-label, single arm, multicenter, prospective, observational study assessing the efficacy and safety of subsequent treatment after initiation of intravitreal injection of ranibizumab 0.5 mg in diabetic macular edema patients with impaired visual acuity through individualized treatment in routine clinical practice in Japan

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms MERCURY study
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top